Allyx Therapeutics updates May offering to $27.9 million
An October amendment increased the cumulative amount sold in the neurodegeneration drug developer’s existing offering.
Allyx Therapeutics reported $27,927,729 in cumulative securities sales in an amendment filed on October 21, 2026, updating an equity and warrant offering first disclosed on May 11.
The original notice reported $26,427,730 sold after the first sale on May 4. The amendment adds $1,499,999 to that cumulative total, leaving $2,072,270 unsold against a $29,999,999 target. It reports 33 investors without naming the subscribers.
The New Haven company develops investigational oral therapies intended to protect synapses in neurodegenerative disease. Its lead candidate, ALX-001, is being developed for Alzheimer’s and Parkinson’s disease.